Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188761 | 0.86 | BACE1 (0.42) | BACE1BACE2CYP2D6KCNH2 | |
| SCHEMBL3187951 | 0.85 | BRAF (0.34) | BACE1BACE2CYP2D6KCNH2AAK1 | |
| SCHEMBL15839603 | 0.83 | BACE1 (0.49) | BACE1KCNH2 | |
| SCHEMBL3191096 | 0.82 | BACE1 (0.40) | BACE1BACE2CYP2D6KCNH2CTSD | |
| SCHEMBL3191088 | 0.82 | BACE1 (0.40) | BACE1BACE2CYP2D6KCNH2CTSD | |
| SCHEMBL1420827 | 0.78 | BACE1 (0.35) | BACE1AAK1BRAFIDH1LCK | |
| SCHEMBL13533305 | 0.77 | HCRTR1 (0.38) | BACE1AAK1CTSDLCK | |
| SCHEMBL1422427 | 0.75 | BACE1 (0.57) | BACE1BACE2CYP2D6KCNH2CTSD | |
| SCHEMBL1421185 | 0.74 | AAK1 (0.35) | BACE1AAK1BRAFLCK | |
| SCHEMBL15839655 | 0.72 | BACE1 (0.47) | BACE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297120-B1 | AMINODIHYDROTHIAZINE DERIVATIVES AS BACE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7648983-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090275566-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275566-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CYP2D6 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.